Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Research reveals Eli Lilly's GLP-1 drug, tirzepatide, temporarily suppresses food cravings in a patient's brain reward center. While initial effects were promising, the impact faded over time. Results ...

The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to ...

Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Eli Lilly is well on its way to the trillion-dollar club. The stock price is up 30% so far this year; with a total ...

Eli Lilly and Novo Nordisk’s competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh. Who is winning?

Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.

Shares of Mangoceuticals surged 28% ‌to $2.25 in premarket trading. U.S. regulations allow compounding pharmacies to copy ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...